-
1
-
-
0037204196
-
Clinical practice. Antibiotic-associated diarrhea
-
Bartlett JG,. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334-9.
-
(2002)
N Engl J Med
, vol.346
, pp. 334-339
-
-
Bartlett, J.G.1
-
2
-
-
0035180464
-
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: A prospective study
-
Wiström J, Norrby SR, Myhre EB, et al,. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50.
-
(2001)
J Antimicrob Chemother
, vol.47
, pp. 43-50
-
-
Wiström, J.1
Norrby, S.R.2
Myhre, E.B.3
-
4
-
-
66949160435
-
Antibiotic associated diarrhea in children
-
Alam S, Mushtaq M,. Antibiotic associated diarrhea in children. Indian Pediatr 2009; 46: 491-6.
-
(2009)
Indian Pediatr
, vol.46
, pp. 491-496
-
-
Alam, S.1
Mushtaq, M.2
-
5
-
-
33645455337
-
Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease
-
McFarland LV,. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-22.
-
(2006)
Am J Gastroenterol
, vol.101
, pp. 812-822
-
-
McFarland, L.V.1
-
6
-
-
84905675648
-
Expert consensus document. the International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic
-
Hill C, Guarner F, Reid G, et al,. Expert consensus document. The International Scientific Association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-14.
-
(2014)
Nat Rev Gastroenterol Hepatol
, vol.11
, pp. 506-514
-
-
Hill, C.1
Guarner, F.2
Reid, G.3
-
7
-
-
24344493550
-
Meta-analysis: Non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea
-
Szajewska H, Mrukowicz J,. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005; 22: 365-72.
-
(2005)
Aliment Pharmacol Ther
, vol.22
, pp. 365-372
-
-
Szajewska, H.1
Mrukowicz, J.2
-
9
-
-
68049122102
-
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
-
The PRISMA Group.
-
Moher D, Liberati A, Tetzlaff J, Altman DG,; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
-
(2009)
PLoS Med
, vol.6
, pp. e1000097
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
10
-
-
70350275459
-
-
(eds). Updated October 2013. The GRADE Working Group, 2013. Available at.
-
Schünemann H, Brozek J, Guyatt G, Oxman A, (eds). GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available at: http://www.guidelinedevelopment.org/handbook.
-
GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations
-
-
Schünemann, H.1
Brozek, J.2
Guyatt, G.3
Oxman, A.4
-
11
-
-
79951951792
-
GRADE guidelines: 2. Framing the question and deciding on important outcomes
-
Guyatt GH, Oxman AD, Kunz R, et al,. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395-400.
-
(2011)
J Clin Epidemiol
, vol.64
, pp. 395-400
-
-
Guyatt, G.H.1
Oxman, A.D.2
Kunz, R.3
-
12
-
-
0030922816
-
Bias in meta-analysis detected by a simple, graphical test
-
Egger M, Smith GD, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34.
-
(1997)
Br Med J
, vol.315
, pp. 629-634
-
-
Egger, M.1
Smith, G.D.2
Schneider, M.3
Minder, C.4
-
13
-
-
15044347921
-
Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: A randomized double-blind placebo-controlled trial
-
Kotowska M, Albrecht P, Szajewska H,. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21: 583-90.
-
(2005)
Aliment Pharmacol Ther
, vol.21
, pp. 583-590
-
-
Kotowska, M.1
Albrecht, P.2
Szajewska, H.3
-
14
-
-
0017403979
-
Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée: étude multicentrique par 25 médicins de 388 cas
-
Adam J, Barret A, Barret-Bellet C,. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée: étude multicentrique par 25 médicins de 388 cas. Gaz Med Fr 1977; 84: 2072-8.
-
(1977)
Gaz Med Fr
, vol.84
, pp. 2072-2078
-
-
Adam, J.1
Barret, A.2
Barret-Bellet, C.3
-
15
-
-
0024562960
-
Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study
-
Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G,. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 1989; 96: 981-8.
-
(1989)
Gastroenterology
, vol.96
, pp. 981-988
-
-
Surawicz, C.M.1
Elmer, G.W.2
Speelman, P.3
McFarland, L.V.4
Chinn, J.5
Van Belle, G.6
-
16
-
-
0000650388
-
The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients
-
Lewis SJ, Potts LF, Barry RE,. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 171-4.
-
(1998)
J Infect
, vol.36
, pp. 171-174
-
-
Lewis, S.J.1
Potts, L.F.2
Barry, R.E.3
-
17
-
-
0028985777
-
Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo
-
McFarland LV, Surawicz CM, Greenberg RN, et al,. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-48.
-
(1995)
Am J Gastroenterol
, vol.90
, pp. 439-448
-
-
McFarland, L.V.1
Surawicz, C.M.2
Greenberg, R.N.3
-
18
-
-
84901701743
-
Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children
-
Chinese.
-
Zhao HM, Ou-Yang HJ, Duan BP, et al,. Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children. Zhongguo Dang Dai Er Ke Za Zhi 2014; 16: 230-3 Chinese.
-
(2014)
Zhongguo Dang Dai Er Ke Za Zhi
, vol.16
, pp. 230-233
-
-
Zhao, H.M.1
Ou-Yang, H.J.2
Duan, B.P.3
-
19
-
-
0019540290
-
Double blind clinical trial on the use of ultra-levure in the prophylaxis of antibiotic induced gastro-intestinal and mucocutaneous disorders
-
Monteiro E, Fernandes JP, Vieira MR, et al,. Double blind clinical trial on the use of ultra-levure in the prophylaxis of antibiotic induced gastro-intestinal and mucocutaneous disorders. Acta Med Port 1981; 3: 143-5.
-
(1981)
Acta Med Port
, vol.3
, pp. 143-145
-
-
Monteiro, E.1
Fernandes, J.P.2
Vieira, M.R.3
-
20
-
-
54349088275
-
[Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment]
-
Spanish.
-
Bravo MV, Bunout D, Leiva L, et al,. [Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment]. Rev Med Chil 2008; 136: 981-8. Spanish.
-
(2008)
Rev Med Chil
, vol.136
, pp. 981-988
-
-
Bravo, M.V.1
Bunout, D.2
Leiva, L.3
-
21
-
-
33645544410
-
Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea
-
Can M, Bes,irbellioglu BA, Avci IY, Beker CM, Pahsa A,. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Med Sci Monit 2006; 12: PI19-22.
-
(2006)
Med Sci Monit
, vol.12
, pp. PI19-PI22
-
-
Can, M.1
Bes Irbellioglu, B.A.2
Avci, I.Y.3
Beker, C.M.4
Pahsa, A.5
-
22
-
-
84983384568
-
Saccharomyces boulardii in the prevention of antibiotic associated diarrhea in children: A randomized controlled trial
-
Casem RAO,. Saccharomyces boulardii in the prevention of antibiotic associated diarrhea in children: a randomized controlled trial. Pediatr Infect Dis Soc Philipp J 2013; 14: 70-6.
-
(2013)
Pediatr Infect Dis Soc Philipp J
, vol.14
, pp. 70-76
-
-
Casem, R.A.O.1
-
23
-
-
4344576452
-
The probiotic effect of Saccharomyces boulardii in a pediatric age group
-
Erdeve O, Tiras U, Dallar Y,. The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatr 2004; 50: 234-6.
-
(2004)
J Trop Pediatr
, vol.50
, pp. 234-236
-
-
Erdeve, O.1
Tiras, U.2
Dallar, Y.3
-
24
-
-
84861908072
-
Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: A single-center, randomized, double-blind, placebo-controlled trial
-
Pozzoni P, Riva A, Bellatorre AG, et al,. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012; 107: 922-31.
-
(2012)
Am J Gastroenterol
, vol.107
, pp. 922-931
-
-
Pozzoni, P.1
Riva, A.2
Bellatorre, A.G.3
-
25
-
-
84891614402
-
Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections
-
Shan LS, Hou P, Wang ZJ, et al,. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes 2013; 4: 329-34.
-
(2013)
Benef Microbes
, vol.4
, pp. 329-334
-
-
Shan, L.S.1
Hou, P.2
Wang, Z.J.3
-
26
-
-
84929273917
-
Intervention study on Saccharomyces boulardii with proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori related peptic ucer
-
Chu Y, Zhu H, Zhou Y, Lv L, Hu J,. Intervention study on Saccharomyces boulardii with proton pump inhibitor (PPI)-based triple therapy for Helicobacter pylori related peptic ucer. African J Pharm Pharmacol 2012; 6: 2900-4.
-
(2012)
African J Pharm Pharmacol
, vol.6
, pp. 2900-2904
-
-
Chu, Y.1
Zhu, H.2
Zhou, Y.3
Lv, L.4
Hu, J.5
-
27
-
-
34547569295
-
Efficacy and safety of Saccharomyces boulardii in the 14- day triple anti-Helicobacter pylori therapy: A prospective randomized placebo-controlled double-blind study
-
Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S,. Efficacy and safety of Saccharomyces boulardii in the 14- day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309-16.
-
(2007)
Helicobacter
, vol.12
, pp. 309-316
-
-
Cindoruk, M.1
Erkan, G.2
Karakan, T.3
Dursun, A.4
Unal, S.5
-
28
-
-
0036840803
-
Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study
-
Cremonini F, di Caro S, Covino M, et al,. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744-9.
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 2744-2749
-
-
Cremonini, F.1
Di Caro, S.2
Covino, M.3
-
29
-
-
29244491643
-
Eficacy and safety of Saccharomyces boulardii in prevention of antibioticassociated diarrhoea due to Helicobacter pylori eradication
-
Duman DG, Bor S, Ozutemiz O, et al,. Eficacy and safety of Saccharomyces boulardii in prevention of antibioticassociated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17: 1357-61.
-
(2005)
Eur J Gastroenterol Hepatol
, vol.17
, pp. 1357-1361
-
-
Duman, D.G.1
Bor, S.2
Ozutemiz, O.3
-
30
-
-
85017747129
-
A lyophilized form of Saccharomyces boulardii enhances the Helicobacter pylori eradication rates of omeprazole-triple therapy in patients with peptic ulcer disease or functional dyspepsia
-
Kyriakos N, Papamichael K, Roussos A, et al,. A lyophilized form of Saccharomyces boulardii enhances the Helicobacter pylori eradication rates of omeprazole-triple therapy in patients with peptic ulcer disease or functional dyspepsia. Hospital Chronicles 2013; 8: 1-7.
-
(2013)
Hospital Chronicles
, vol.8
, pp. 1-7
-
-
Kyriakos, N.1
Papamichael, K.2
Roussos, A.3
-
31
-
-
77952139915
-
The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori
-
Song MJ, Park DI, Park JH, et al,. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010; 15: 206-13.
-
(2010)
Helicobacter
, vol.15
, pp. 206-213
-
-
Song, M.J.1
Park, D.I.2
Park, J.H.3
-
32
-
-
84940793089
-
The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children
-
Bin Z, Ya-Zheng X, Zhao-Hui D, Bo C, Li-Rong J, Vandenplas Y,. The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr Gastroenterol Hepatol Nutr 2015; 18: 17-22.
-
(2015)
Pediatr Gastroenterol Hepatol Nutr
, vol.18
, pp. 17-22
-
-
Bin, Z.1
Ya-Zheng, X.2
Zhao-Hui, D.3
Bo, C.4
Li-Rong, J.5
Vandenplas, Y.6
-
33
-
-
84888787700
-
The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of H. Pylori: A randomized controlled trial
-
Zojaji H, Ghobakhlou M, Rajabalinia H, et al,. The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of H. pylori: a randomized controlled trial. Gastroenterol Hepatol Bed Bench 2013; 6 (Suppl. 1): S99-104.
-
(2013)
Gastroenterol Hepatol Bed Bench
, vol.6
, pp. S99-S104
-
-
Zojaji, H.1
Ghobakhlou, M.2
Rajabalinia, H.3
-
34
-
-
77952615260
-
Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
-
McFarland LV,. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010; 16: 2202-22.
-
(2010)
World J Gastroenterol
, vol.16
, pp. 2202-2222
-
-
McFarland, L.V.1
-
35
-
-
84857520779
-
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
-
Kelesidis T, Pothoulakis C,. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol 2012; 5: 111-25.
-
(2012)
Therap Adv Gastroenterol
, vol.5
, pp. 111-125
-
-
Kelesidis, T.1
Pothoulakis, C.2
-
36
-
-
0032919855
-
Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
-
Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C,. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67: 302-7.
-
(1999)
Infect Immun
, vol.67
, pp. 302-307
-
-
Castagliuolo, I.1
Riegler, M.F.2
Valenick, L.3
LaMont, J.T.4
Pothoulakis, C.5
-
37
-
-
0035077712
-
Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice
-
Qamar A, Aboudola A, Warny M, et al,. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69: 2762-5.
-
(2001)
Infect Immun
, vol.69
, pp. 2762-2765
-
-
Qamar, A.1
Aboudola, A.2
Warny, M.3
-
38
-
-
33747699728
-
Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis
-
Chen X, Kokkotou EG, Mustafa N, et al,. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 2006; 281: 24449-54.
-
(2006)
J Biol Chem
, vol.281
, pp. 24449-24454
-
-
Chen, X.1
Kokkotou, E.G.2
Mustafa, N.3
-
39
-
-
0036300891
-
Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii
-
Tasteyre A, Barc MC, Karjalainen T, et al,. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microbiol Pathogens 2002; 32: 219-25.
-
(2002)
Microbiol Pathogens
, vol.32
, pp. 219-225
-
-
Tasteyre, A.1
Barc, M.C.2
Karjalainen, T.3
-
40
-
-
0027516691
-
Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum
-
Pothoulakis C, Kelly CP, Joshi MA, et al,. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104: 1108-15.
-
(1993)
Gastroenterology
, vol.104
, pp. 1108-1115
-
-
Pothoulakis, C.1
Kelly, C.P.2
Joshi, M.A.3
-
41
-
-
84891816574
-
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
-
Goldenberg JZ, Ma SS, Saxton JD, et al,. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5: CD006095.
-
(2013)
Cochrane Database Syst Rev
, vol.5
, pp. CD006095
-
-
Goldenberg, J.Z.1
Ma, S.S.2
Saxton, J.D.3
-
42
-
-
84860708876
-
Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and meta-analysis
-
Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, et al,. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307: 1959-69.
-
(2012)
JAMA
, vol.307
, pp. 1959-1969
-
-
Hempel, S.1
Newberry, S.J.2
Maher, A.R.3
Wang, Z.4
Miles, J.N.5
Shanman, R.6
-
43
-
-
84885103912
-
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: Systematic review and meta-analysis
-
Pattani R, Palda VA, Hwang SW, Shah PS,. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med 2013; 7: e56-67.
-
(2013)
Open Med
, vol.7
, pp. e56-e67
-
-
Pattani, R.1
Palda, V.A.2
Hwang, S.W.3
Shah, P.S.4
-
44
-
-
84928884954
-
Deciphering meta-analytic results: A mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections
-
McFarland LV,. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. Benef Microbes 2015; 6: 189-94.
-
(2015)
Benef Microbes
, vol.6
, pp. 189-194
-
-
McFarland, L.V.1
-
45
-
-
81355160270
-
Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection
-
Bavishi C, Dupont HL,. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011; 34: 1269-81.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 1269-1281
-
-
Bavishi, C.1
Dupont, H.L.2
-
46
-
-
79951983392
-
Use of acid-suppressive drugs and risk of pneumonia: A systematic review and meta-analysis
-
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS,. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183: 310-9.
-
(2011)
CMAJ
, vol.183
, pp. 310-319
-
-
Eom, C.S.1
Jeon, C.Y.2
Lim, J.W.3
Cho, E.G.4
Park, S.M.5
Lee, K.S.6
-
47
-
-
77749254707
-
Safety of probiotics in patients receiving nutritional support: A systematic review of case reports, randomized controlled trials, and nonrandomized trials
-
Whelan K, Myers CE,. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 2010; 91: 687-703.
-
(2010)
Am J Clin Nutr
, vol.91
, pp. 687-703
-
-
Whelan, K.1
Myers, C.E.2
-
48
-
-
77954424086
-
Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients
-
Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE,. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105: 1636-41.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1636-1641
-
-
Gao, X.W.1
Mubasher, M.2
Fang, C.Y.3
Reifer, C.4
Miller, L.E.5
|